2-cyano-N-((ethylamino)carbonyl)-2-(methoxyimino)acetamide | 57966-95-7

• 物质功能分类: 化学农药原药 - 杀菌剂 - 其他杀菌剂
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: 2-cyano-N-((ethylamino)carbonyl)-2-(methoxyimino)acetamide
• 英文别名: 2-cyano-N-(ethylcarbamoyl)-2-methoxyiminoacetamide；1-(2-cyano-2-methoxyiminoacetyl)-3-ethyl-urea；(1Z)-2-(ethylcarbamoylamino)-N-methoxy-2-oxoethanimidoyl cyanide
• CAS: 57966-95-7
• 化学式: C₇H₁₀N₄O₃
• 分子量: 198.181
• InChiKey: XERJKGMBORTKEO-WZUFQYTHSA-N

物化性质

• 熔点：
  160-161°
• 沸点：
  335.48°C (rough estimate)
• 密度：
  1.3841 (rough estimate)
• 闪点：
  100 °C
• 溶解度：
  二甲基亚砜：100 mg/mL（504.59 mM）
• LogP：
  0.590
• 颜色/状态：
  Colorless crystals
• 气味：
  Odorless
• 蒸汽压力：
  1.13X10-6 mm Hg at 20 °C
• 分解：
  When heated to decomposition it emits toxic vapors of /nitrogen oxides/.
• 解离常数：
  pKa = 9.7 (decomposes)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  5

ADMET

代谢

在粪便中完整地检测到了（14）C-cymoxanil（小于1%）和IN W3595，但大部分放射性为（14）C-glycine（大约9-13%）。根据数据，代谢途径涉及cymoxanil水解成IN W3595，然后IN W3595降解为glycine，glycine进而被纳入天然成分或进一步代谢。

... In feces intact (14)C-cymoxanil (< 1%) and IN W3595 was detected, but the majority of radioactivity was (14)C-glycine (about 9 - 13%). Based on the data, the metabolic pathway involves hydrolysis of cymoxanil to IN W3595, which is then degraded to glycine, which in turn is incorporated into natural constituents or further metabolized.

来源:Hazardous Substances Data Bank (HSDB)

代谢

IN-U3204（1-乙基-5,6-二-2,4(1H,3H)吡啶二酮）在接受了120毫克/千克DPX-3217处理的动物的两性混合0-48小时尿样中被检测到，以及在正在进行的低剂量胆管瘘研究中，接受了2.5毫克/千克处理的动物的两性混合0-24小时尿样中也被检测到。后一组被包括进来是为了确保IN-U3204的存在不是储存过程中的伪迹；尽管在两组中检测到的IN-U3204水平看似较低，但它确实在两组中都被检测到了。

... IN-U3204 (1-ethyl-5,6-di-2,4(1H,3H) pyridinedione) was detected in pooled 0-48 hr urine samples, both sexes, from animals treated with 120 mg/kg DPX-3217 and in pooled 0-24 hr samples, both sexes, from animals treated with 2.5 mg/kg in an ongoing low dose biliary fistula study. The latter group was included to ensure that the presence of IN-U3204 was not an artifact of storage; IN-U3204 was detected in both groups, though at apparently low levels.

来源:Hazardous Substances Data Bank (HSDB)

代谢

/2-(14)C-DPX-T3217/ 以玉米油为溶剂给大鼠单次给药，剂量组为：2.5 & 120 mg/kg，0.5 & 2 mL/只动物（约为10 & ~20 uCi/只动物，分别为D组和E组），以及一个多次给药组：连续14天每天给药2.5 mg/kg，随后给予标记剂量的2.5 mg/kg（F组）。在5性别/剂量的方案中，通过HPLC和TLC在排泄物中检测到的初级代谢物是IN-W3595（2-氰基-2-甲氧亚基乙酸）和极性成分（甘氨酸和其他氨基酸结合物）；在D组雄性大鼠中，24小时内：58%的给药剂量（AD）出现在尿液中（8.6%为IN-W3595，46.5%为极性物质），21.9%出现在粪便中（14%可提取，<1% IN-W3595，13.1%极性物质）。在D组雌性大鼠中，64.2%的AD出现在尿液中（16.1% IN-W3595，45.2%极性物质），16.3%出现在粪便中（10.1%可提取，<1% IN-W3595，8.7%极性物质）。在E组雄性大鼠中，70.3%的AD出现在尿液中（26.3% IN-W3595，40.3%极性物质），16.1%出现在粪便中（11.3%可提取，<1% IN-W3595，8.6%极性物质）。在E组雌性大鼠中，73%的AD出现在尿液中（33% IN-W3595，36.7%极性物质），17.1%出现在粪便中（11.5%可提取，<1% IN-W3595，8.5%极性物质）。在F组雄性大鼠中，66.2%的AD出现在尿液中（6.5% IN-W3595，55%极性物质），14.5%出现在粪便中（9%可提取，<1% IN-W3595，8.9%极性物质）。在F组雌性大鼠中，63.1%的AD出现在尿液中（11.1% IN-W3595，46.6%极性物质），19.4%出现在粪便中（12.3%可提取，<1% IN-W3595，12.2%极性物质）。/IN-W3595代谢物/

/2-(14)C-DPX-T3217/ was administered /to rats/ in corn oil to/ single dose groups: 2.5 & 120 mg/kg, 0.5 & 2 mL/animal (~10 & ~20 uCi/animal, groups D & E, respectively) and a multiple dose group: daily administration at 2.5 mg/kg for 14 days followed by labeled dose at 2.5 mg/kg (group F). /In a/ 5/sex/dose regimen, the primary metabolites detected by HPLC and TLC in excreta were IN-W3595 (2-cyano-2-methoxyimino acetic acid) and polar components (glycine and other amino acid conjugates); In group D males, 24 hr: 58% of /administered dose (AD)/ in urine (8.6% as IN-W3595, 46.5% as polars), 21.9% in feces (14% extractable, <1% IN-W3595, 13.1% polars). In /group D/ females, 64.2% of AD /appeared/ in urine (16.1% IN-W3595, 45.2% polars), 16.3% in feces (10.1% extractable, <1% IN-W3595, 8.7% polars). In group E males, 70.3% of AD /appeared/ in urine (26.3% IN-W3595, 40.3% polars), 16.1% in feces (11.3% extractable, <1% IN-W3595, 8.6% polars). /In group E/ females, 73% of AD in urine (33% IN-W3595, 36.7% polars), 17.1% in feces (11.5% extractable, <1% IN-W3595, 8.5% polars). In group F males, 66.2% of AD /appeared/ in urine (6.5% IN-W3595, 55% polars), 14.5% in feces (9% extractable, <1% IN-W3595, 8.9% polars). In group F females, 63.1% of AD /appeared/ in urine (11.1% IN-W3595, 46.6% polars), 19.4% in feces (12.3% extractable, <1% IN-W3595, 12.2% polars). /IN-W3595 metabolite/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 致癌性证据

癌症分类：不太可能对人类致癌

Cancer Classification: Not Likely to be Carcinogenic to Humans

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 副作用

皮肤致敏剂 - 一种可以诱导皮肤产生过敏反应的制剂。

Skin Sensitizer - An agent that can induce an allergic reaction in the skin.

来源:Haz-Map, Information on Hazardous Chemicals and Occupational Diseases

毒理性

• 毒性数据

LCLo（大鼠）= 4,980 毫克/立方米/4小时

LCLo (rat) = 4,980 mg/m3/4h

来源:Haz-Map, Information on Hazardous Chemicals and Occupational Diseases

毒理性

• 解毒与急救

/SRP:/ 立即急救：确保已经进行了充分的中和。如果患者停止呼吸，请开始人工呼吸，最好使用需求阀复苏器、球囊阀面罩设备或口袋面罩，按训练操作。如有必要，执行心肺复苏。立即用缓慢流动的水冲洗受污染的眼睛。不要催吐。如果患者呕吐，让患者向前倾或将其置于左侧（如果可能的话，头部向下），以保持呼吸道畅通，防止吸入。保持患者安静，维持正常体温。寻求医疗救助。 /毒物A和B/

/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

/SRP:/ 基本治疗：建立专利气道（如有需要，使用口咽或鼻咽气道）。如有必要，进行吸痰。观察呼吸不足的迹象，如有需要，辅助通气。通过非循环呼吸面罩以10至15升/分钟的速度给予氧气。监测肺水肿，如有必要，进行治疗……。监测休克，如有必要，进行治疗……。预防癫痫发作，如有必要，进行治疗……。对于眼睛污染，立即用水冲洗眼睛。在运输过程中，用0.9%的生理盐水（NS）持续冲洗每只眼睛……。不要使用催吐剂。对于摄入，如果患者能吞咽、有强烈的干呕反射且不流口水，则用温水冲洗口腔，并给予5毫升/千克，最多200毫升的水进行稀释……。在去污后，用干燥的无菌敷料覆盖皮肤烧伤……。/毒药A和B/

/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

赛默昔尼尔（Cymoxanil）能够迅速被吸收，给药后4小时内血液和血浆中达到最大浓度。在48小时内，观察到尿液和粪便中快速且几乎完全排除了所给予的放射性剂量。排泄主要通过尿液（64 - 75%），粪便（16 - 24%）和呼出气体（< 5%）进行。在性别、剂量水平或单次或多次给药之间，残留物轮廓或消除率没有显著差异。没有检测到生物累积的证据。DPX-T3217被广泛代谢，尿液和粪便中仅检测到微量级别的所给予的（14）C-赛默昔尼尔。...

Cymoxanil is rapidly absorbed and maximum concentrations in the blood and plasma is reached within 4 hours after dosing. Rapid and almost complete elimination of the administered radioactive dose was observed in urine and feces within 48 hours. Excretion is primarily by urine (64 - 75%), fecal (16 - 24%) and expired air (< 5%) of the administered dose. There is no significant difference in residue profiles or elimination rates between sexes, dose levels, or single or multiple dosing. No evidence of bioaccumulation was detected. DPX-T3217 is metabolized extensively and only trace level of the administered (14)C-cymoxanil was detected in the urine and feces. ...

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

五只/性别的大鼠通过胆管插管口服给予了2.5毫克/千克的(14)C-Cymoxanil（放射性纯度=98%; 14.09 uCi/mg），以玉米油悬浮液形式。在48小时的时间内收集尿液、粪便和胆汁，之后处死动物并收集全血、肝脏、肾脏和剩余尸体以测量放射性标记。...在48小时内，超过85%的测试化合物通过尿液（大约65%）、粪便（大约14%）和胆汁（大约7%）排出，大部分在最初的24小时内排出；极性氨基酸结合物是尿液中（大约45-50%）和胆汁中（大约4-6%）发现的主要代谢物类别；代谢物A（未知）和IN-W3595/(2-氰基-2-甲氧亚氨基乙酸)/在尿液中的浓度较低（<10%）。IN-W3595在雌性大鼠尿液中的浓度（7.7%）高于雄性（2.8%）；代谢物A在胆汁中未发现。

Five SD rats/sex with cannulated bile ducts were dosed orally with 2.5 mg/kg of (14)C-Cymoxanil (radiochemical purity = 98%; 14.09 uCi/mg) as a corn oil suspension. Urine, feces, and bile were collected over a 48 h period, after which the animals were terminated and whole blood, liver, kidneys, and residual carcass were collected for measurement of radiolabel. ...More than 85% of the test compound was eliminated in urine ( approximately 65%), feces (approximately 14%), and bile (approximately 7%) within 48 hr in both sexes, with most elimination occurring with the first 24 hr; polar amino acid conjugates comprised the major class of metabolites found in both urine (approximately 45-50%) and bile (approximately 4-6%); Metabolite A (unknown) and IN-W3595 /(2-cyano-2-methoxyimino acetic acid)/ were found at much lower concentrations (< 10%) in urine. IN-W3595 was found at higher concentrations in the urine of females (7.7%) as compared to males (2.8%); Metabolite A was not found in bile.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

为了研究2-(14)C-DPX-T3217在大鼠体内的吸收、分布、代谢和排泄，以玉米油为溶剂，给大鼠口服2.5毫克/千克和120毫克/千克剂量的药物，每只动物的给药体积分别为0.5毫升和2毫升。放射性活度分别约为10微居里和20微居里/动物。高剂量是根据预期轻微毒性来设定的。通过单次灌胃给药：每组每性别3只动物用于血液药代动力学研究，5只用于排泄/分布研究，8只用于组织分布研究；多次给药（在2.5毫克/千克剂量下冷给药14天，随后给予标记剂量）：每组每性别5只动物；血液/血浆和组织残留物轮廓在各组之间没有显著差异。最大血液浓度在4小时内达到；高剂量（两个性别）和多次低剂量（仅限雄性）时，相对粪便排泄量可能略有减少。在比较性别、剂量或单次与多次给药方案时，排泄时间或途径没有显著差异。包括所有剂量组，24小时内57-65%的给药剂量（AD）在尿液中回收，5-17%在粪便中；96小时内63-75%在尿液中回收，16-24%在粪便中；在96小时时，组织中剩余的AD小于1%（在肾脏、肝脏和皮肤中找到最高水平）。

/To study the absorption, distribution, metabolism, and excretion of 2-(14)C-DPX-T3217 in rats, doses of/ 2.5 & 120 mg/kg in corn oil /at/ 0.5 & 2 mL/animal, /were administered. Radioactivity amounted to/ ~10 & ~20 uCi/animal, respectively. /High dose/ set by expectation of slight toxicity. /With/ single gavage administration: 3/sex/dose - blood pharmacokinetics, 5/sex/dose - elimination/distribution, 8/sex/dose - tissue distribution; multiple administration (cold dosing at 2.5 mg/kg for 14 days followed by labeled dose): 5/sex; no significant differences between groups in blood/plasma and tissue residue profiles. Max. blood concentrations were attained by 4 hr; with the possible exception of a somewhat decreased relative fecal excretion at the high dose (both sexes) and at the multiple low dose (males only). No significant differences in excretion time or route were seen when comparing sexes, doses, or single vs. multiple dosing regimens. Including all dose groups, 57-65% of the administered dose (AD) recovered in urine & 5-17% in feces by 24 hr, 63-75% in urine & 16-24% in feces by 96 hr; at 96 hr <1% of AD remained in tissues (highest levels found in kidney, liver, & skin).

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

(14)C-Cymoxanil施用到番茄植株的根系或叶面上，通过放射自显影、燃烧和薄层色谱分析水或甲醇提取物来跟踪其吸收、传输和降解情况。Cymoxanil在1小时内被根系吸收，并在16小时内传输到子叶、茎和叶片。该化合物在16-44小时内主要降解为甘氨酸，在根系和所有地上部分。当将(14)C-cymoxanil施用到五叶植物的叶2表面时，与单独施用(14)C-cymoxanil的植物相比，使用氧化噁菌灵和(14)C-cymoxanil混合物处理的植物显示出增强的吸收、传输和降解（主要转化为甘氨酸）现象。根系施用的数据确认了cymoxanil在番茄植株中是一种具有短暂持效的系统化合物。叶面施用的数据表明，cymoxanil、氧化噁菌灵和代森锰锌之间在控制由霜霉目引起的植物病害方面已知的协同作用，并不是由于其他杀菌剂存在时cymoxanil降解延迟所致；协同作用的机制尚未阐明。

(14)C-Cymoxanil was applied to either the root system or to the foliage of tomato plants and its uptake, translocation and degradation was followed using autoradiography, combustion and thin-layer chromatographic analyses of water or methanolic extracts. Cymoxanil was taken up by the root system within 1 hr and translocated to cotyledons, stem and leaves within 16 hr. The compound was degraded, mostly to glycine, within 16-44 h, in the root and all parts of the shoot. When applied to the surface of leaf 2 of five-leaf plants, enhanced uptake, translocation and degradation (mainly to glycine) of (14)C-cymoxanil was observed in plants treated with a mixture of oxadixyl and (14)C-cymoxanil, compared with plants treated with (14)C-cymoxanil alone. Root application data confirm that cymoxanil is a systemic compound with a short persistence in tomato plants. Foliage application data suggest that the well-documented synergistic interaction between cymoxanil, oxadixyl and mancozeb in controlling plant diseases caused by Peronosporales does not result from a delayed degradation of cymoxanil in the presence of the other fungicides; the mechanism of synergism has not yet been elucidated.

来源:Hazardous Substances Data Bank (HSDB)

安全信息

• 危险等级：
  9
• 危险品标志：
  Xn
• 安全说明：
  S36/37,S60,S61
• 危险类别码：
  R22,R50/53,R43
• WGK Germany：
  3
• 海关编码：
  2926909038
• 危险品运输编号：
  UN 3077
• RTECS号：
  AB5957000

制备方法与用途

毒性

原药对大鼠急性经口LD₅₀为1196毫克/公斤，豚鼠为1096毫克/公斤。兔急性经皮LD₅₀大于3000毫克/公斤。该物质对眼睛有轻度刺激，但无皮肤刺激作用。Ames试验呈阴性，表明其无致突变作用。

虹鳟鱼LC₅₀为18.7毫克/升（96小时），野鸭和鹌鹑的LC₅₀分别为大于10000毫克/公斤饲料和2847毫克/公斤饲料。该物质无积累毒性。

化学性质

霜脲氰是一种白色结晶体，熔点为160～161℃，相对密度1.31（25℃），蒸气压约8×10^-5帕斯卡（25℃）。在25℃时的溶解度分别为：丙酮10.5%，二甲基甲酰胺18.5%，氯仿10.3%，甲醇4.1%，苯0.2%，己烷0.1%，水0.1%。正常贮存条件下稳定。

用途

霜脲氰是一种高效杀菌剂，具有内吸作用，与保护性杀菌剂混用能提高残留活性。它对霜霉目真菌（包括疫霉属、霜霉属和单轴霉属）有效。推荐剂量为0.9～1.2克/100平方米，用于防治马铃薯晚疫病和葡萄霜霉病。

此外，霜脲氰还适用于防治番茄、黄瓜等作物的霜霉病和晚疫病，以及黄瓜霜霉病。

生产方法

霜脲氰的合成过程包括以下步骤：

1. N-氰乙酰基-N-乙基脲 的制备：将98克N-乙基脲、94克氰乙酸和200克乙酸酐混合，升温至60℃并保持3小时。冷却后减压脱去乙酸，并用水处理结晶，最终得白色细针状结晶，熔点173℃。

2. 2-氰基-2-肟基乙酰胺 的制备：在氮气氛围下将甲醇、水与N-氰乙酰基-N-乙基脲混合，在40℃反应1小时后加入6摩尔/升盐酸，继续反应2小时。调节pH值至7～8。

3. 霜脲氰 的合成：缓加硫酸二甲酯，并用50% NaOH溶液维持pH值在7～8之间，在40℃下反应2小时后冷却至5℃，抽滤、水洗并干燥，再于无水乙醇中重结晶。

类别

• 农药
• 毒性分级：中毒
• 急性毒性：
  • 口服-大鼠 LD₅₀：1100毫克/公斤；
  • 腹腔注射-大鼠 LD₅₀：166毫克/公斤

安全与储存

• 可燃性危险特性：可燃；燃烧时产生有毒氮氧化物烟雾。
• 储运特性：库房通风、低温干燥；与氧化剂、碱类分开存放。
• 灭火剂：泡沫、二氧化碳、砂土、雾状水。

文献信息

• Fungicidal oxime carbamates
  申请人：E.I. DU PONT DE NEMOURS AND COMPANY

  公开号：EP0397345A1

  公开（公告）日：1990-11-14

  A method of controlling plant diseases, especially fungi, using oxime carbamates and analogs thereof and novel compounds within the class. Reason: Rule 8.1.i PCT.

  一种使用肟基氨基甲酸酯及其类似物以及该类中的新颖化合物来控制植物病害，尤其是真菌的方法。 原因：PCT规则8.1.i。
• Fungicidal 4-thixooxazolidin-2-ones and 4-iminooxazolindin-2-ones
  申请人：E.I. DU PONT DE NEMOURS AND COMPANY

  公开号：EP0503798A1

  公开（公告）日：1992-09-16

  This invention pertains to compounds of Formula I including all geometric and stereoisomers, agriculturally suitable salts thereof, agricultural compositions containing them and their use as fungicides.

  这项发明涉及包括所有几何和立体异构体的化合物I的农业适用盐，含有它们的农业组合物以及它们作为杀菌剂的用途。
• N-Formyl phosphonamidothioates
  申请人：E.I. DU PONT DE NEMOURS AND COMPANY

  公开号：EP0322195A1

  公开（公告）日：1989-06-28

  This invention relates to certain N-formyl phosphonamidothioates, agriculturally suitable compositions containing them, and their use as insecticides, acaricides and nematocides.

  这项发明涉及某些N-甲酰磷酰氨基硫酸酯，含有它们的农业适用组合物，以及它们作为杀虫剂、杀螨剂和杀线虫剂的用途。
• Organic Derivatives, Their Salts and Use for the Control of Phytopathogens
  申请人：Filippini Lucio

  公开号：US20090029948A1

  公开（公告）日：2009-01-29

  Organic compounds are described, which are capable of forming quaternary salts, quaternary salts thereof with a structure having general formula (I) and their use for the control of phytopathogen fungi.

  有机化合物被描述为能够形成季铵盐，其带有一般式（I）结构的季铵盐，以及它们用于控制植物病原真菌的用途。
• Insecticidal and acaricidal composition, and methods of using the same
  申请人：AGRO-KANESHO CO., LTD.

  公开号：US20020156115A1

  公开（公告）日：2002-10-24

  The present invention provides an insecticidal or acaricidal composition having an excellent pesticidal effect and a high safety, containing, as an active ingredient, a pyrazolyl compound of the following general formula (I): 1 wherein A represents a hydrogen atom; an alkyl group which may be substituted; an alkenyl group which may be substituted; an alkynyl group which may be substituted; a tri-substituted silyl group substituted with an alkyl group and/or an aryl group: an aryl group which may be substituted; or a heterocyclic group which may be substituted; B represents a single bond; a group of the formula: —(G 1 ) n —G 2 —(G 1 ) m — wherein G 1 represents an oxygen atom, a sulfur atom, a sulfinyl group or a sulfonyl group, G 2 represents an alkylene group, an alkenylene group or an alkynylene group, and n and m are independent from each other and represent 0 or 1; carbonyl group; a group of the formula: —CH 2 —O—N═C(R 3 )— wherein R 3 represents a hydrogen atom, an alkyl group or a haloalkyl group; or a group of the formula: —CH═N—O—(CR 3 R 4 ) n — wherein R 3 and R 4 each represents a hydrogen atom, an alkyl group or a haloalkyl group; and n is 0 or 1, R 1 represents a hydrogen atom; a halogen atom, an alkyl group which may be substituted; an alkenyl group which may be substituted; an alkynyl group which may be substituted; an alkoxyl group which may be substituted; or an aryl group which may be substituted, R 2 represents a hydrogen atom; an alkyl group; a haloalkyl group; or an aryl group which may be substituted, and D represents a group of the formula: —C(═Y)COX wherein X represents a hydroxyl group, an alkoxyl group or an alkylamino group, Y represents a group of the formula: CH—(G 3 ) n —G 4 — wherein G 3 represents an oxygen atom or a sulfur atom, G 4 represents an alkyl group or a haloalkyl group, and n represents 0 or 1, a group of the formula: N—O—G 4 wherein G 4 represents an alkyl group or a haloalkyl group; or a group of the formula: —N(R 5 )CO 2 G 5 wherein R 5 represents an alkyl group, an alkenyl group, an alkynyl group, an alkylthioalkyl group or an alkoxyalkyl group, and G 5 represents an alkyl group.

  本发明提供了一种具有优异杀虫或杀螨效果且具有高安全性的杀虫剂或杀螨剂组合物，其包含以下通式（I）的吡唑基化合物作为活性成分：其中A代表氢原子；可以被取代的烷基基团；可以被取代的烯基基团；可以被取代的炔基基团；取代的三取代硅基团，取代的烷基基团和/或芳基团；可以被取代的芳基团；或可以被取代的杂环基团；B代表单键；具有以下结构的基团：—（G1）n—G2—（G1）m—其中G1代表氧原子、硫原子、亚硫酰基或磺酰基，G2代表烷基基团、烯基基团或炔基基团，n和m是独立的，表示0或1；羰基基团；具有以下结构的基团：—CH2—O—N═C(R3)—其中R3代表氢原子、烷基基团或卤代烷基基团；或具有以下结构的基团：—CH═N—O—（CR3R4）n—其中R3和R4各自代表氢原子、烷基基团或卤代烷基基团；n为0或1，R1代表氢原子；卤素原子、可以被取代的烷基基团；可以被取代的烯基基团；可以被取代的炔基基团；可以被取代的烷氧基基团；或可以被取代的芳基团；R2代表氢原子；烷基基团；卤代烷基基团；或可以被取代的芳基团，D代表以下结构的基团：—C(═Y)COX，其中X代表羟基、烷氧基或烷基氨基，Y代表结构：CH—（G3）n—G4—其中G3代表氧原子或硫原子，G4代表烷基基团或卤代烷基基团，n代表0或1，具有以下结构的基团：N—O—G4其中G4代表烷基基团或卤代烷基基团；或具有以下结构的基团：—N(R5)CO2G5其中R5代表烷基基团、烯基基团、炔基基团、烷基硫基基团或烷氧基烷基基团，G5代表烷基基团。